UBS Raises Price Target on Moderna Ahead of Upcoming Pipeline Reviews
UBS raised its price target for Moderna (NASDAQ:MRNA) from $36 to $45 while maintaining a Neutral rating, citing key pipeline developments. The firm highlighted an upcoming FDA advisory committee meeting scheduled for June 18 regarding Moderna's investigational mRNA influenza vaccine.
Tickers: $MRNA
Topics: biotech pipeline developments price target regulatory review